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Background: Previously, we demonstrated that unlike subcutaneous or intramuscular vaccination, intranasal
vaccination of BALB/c mice with whole Leishmania amazonensis antigens leads to protection against cutaneous
leishmaniasis. Here, the role of parasite serine proteases in the protective immunity was investigated.
Findings: Serine Proteases were partially purified from both soluble (LaSP-Sol) and extracellular (LaSP-Ex) Leishmania
amazonensis promastigote extracts by aprotinin-agarose chromatography. BALB/c mice were intranasally immunized
with LaSP-Sol and LaSP-Ex prior to infection with L. amazonensis. LaSP-Ex but not LaSP-Sol vaccination led to
significantly smaller lesions and parasite burdens as compared with non-vaccinated controls. Protection was
accompanied by systemic Th1 polarization with increased IFN-γ and decreased IL-4 and IL-10 splenic production.
Likewise, increased production of IFN-γ, IL-12 and IL-4 concomitant with decreased TGF-β and TNF-α was locally
observed in the infected footpad.
Conclusion: This study indicates that extracellular serine proteases of L. amazonensis are strong candidates for a
more defined intranasal vaccine against cutaneous leishmaniasis.
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Extracellular serine proteasesBackground
Leishmaniasis is a complex of diseases caused by differ-
ent species of Leishmania protozoans affecting over 11
million people worldwide, with an estimated 1.3 million
new cases a year. Clinical manifestations vary from a lo-
calized cutaneous lesion to lethal visceral infection [1].
Although protective immunity can be acquired following
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article, unless otherwise stated.market against canine visceral leishmaniasis [2], and a
multisubunit recombinant Leishmania vaccine formu-
lated with the MPL-SE adjuvant have progressed to
phase-II clinical trials against cutaneous and visceral
leishmaniasis [3,4], no vaccine has been considered
safe and/or effective enough for human approval [5].
One of the most extensively studied human vaccines is
Leishvacin®, comprised of whole-killed promastigotes of
L. amazonensis, which have been shown to convert the
Montenegro skin test and induce IFN-γ responses in
human volunteers, but its efficacy was not confirmed
after a controlled phase III clinical trial in Colombia
[6], in line with studies in mice and in monkeys showing
that adjuvant-free L. amazonensis antigens is counter-
protective [7,8].ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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cutaneous or intramuscular (i.m.) routes. Mucosal vac-
cination is an effective way to induce active immunity
against infective agents entering the body through the
mucosa, and also an interesting strategy to induce local
and peripheral tolerance to otherwise disease-promoting
antigens such as allergens in a non-invasive fashion [9].
In this context, the nasal mucosa may work in a way
similar to the oral route, but ease of administration,
lower antigen dose and lower degradation of the antigen
are the main positive factors of its use in relation to the
oral route [10].
We previously showed that contrary to the i.m. route,
both oral and intranasal (i.n.) vaccination of mice with
whole L. amazonensis promastigote antigens (LaAg) led
to protection against cutaneous leishmaniasis [7,10,11].
Since LaAg is a complex antigen, we sought to identify
active components for a more defined vaccine. Various
serine proteases (SPs) have been demonstrated in Leish-
mania [12-14]. The observation that neutralization of
SPs and to a lesser extent cysteine proteases with spe-
cific inhibitors rendered LaAg protective via i.m. vaccin-
ation, and that i.m. vaccination with partially purified
soluble serine proteases enhanced mouse susceptibility
to L. amazonensis infection [15], we proposed here to
evaluate the protectiveness of SPs from intracellular and
extracellular parasite extracts against L. amazonensis in-




BALB/c mice were originally obtained from Jackson
Laboratory (Bar Harbor, Maine), and bred and main-
tained at our facilities at Universidade Federal do Rio
de Janeiro using sterilized bedding, filtered water, and
commercial pelleted food, mice were maintained under a
controlled temperature. Female mice were used at 6–8
weeks of age in all experiments. Experiments were ap-
proved under the protocol # CAUAP180 by the Comitte
for Ethical Use of Experimental Animals at CCS/Federal
University of Rio de Janeiro (Brazil).
Parasites
For antigen preparation, Leishmania amazonensis (IFLA/
BR/67/PH8) routinely isolated from mouse lesions were
transformed and maintained as promastigotes at 26°C
in M199 medium containing 10% heat-inactivated fetal
bovine serum (HIFCS, GIBCO Laboratories, Grand
Island, NY). For infection, L. amazonensis (MHOM/BR/
75/Josefa) transfected with green fluorescent protein
(L. amazonensis-GFP) were routinely isolated from mouse
lesions and maintained as promastigotes at 26°C in
M199 medium containing 10% heat-inactivated fetalbovine serum (HIFCS). Parasites were periodically se-
lected for bright fluorescence using 1 mg/mL of geneticin
(Sigma) [16].
LaAg
L. amazonensis promastigote antigens (LaAg) were pre-
pared as previously described [15]. Briefly, stationary-
growth phase promastigotes were washed three times in
phosphate buffered saline (PBS) and subjected to three
cycles of freezing and thawing. LaAg was lyophilized,
stored at −20°C and reconstituted with PBS immediately
prior to use.
Serine protease purification
The soluble serine protease fraction (LaSP-Sol) and extra-
cellular serine protease fraction (LaSP-Ex) were purified as
previously described [12-14]. The soluble serine protease
fraction (LaSP-Sol) was purified from soluble extract
of promastigotes [12] and the extracellular serine pro-
tease fraction (LaSP-Ex) was purified from parasite
culture supernatants [13]. For that, 4 × 1011 promasti-
gotes (2 ×107/mL) were cultured in 2 L of Brain Heart
Infusion (BHI) medium containing 10% HIFCS to the
stationary-phase of growth. Promastigotes were washed
three times in phosphate buffered saline (PBS) and sub-
jected to three cycles of freezing and thawing in Tris–
HCl buffer, pH 7.5, containing 5 mM CaCl2 and the cell
lysate was centrifugated (100,000 × g for 30 min at 4°C)
to remove the non-soluble aggregates, thus producing a
soluble fraction. The culture supernatants (2 L) were pre-
cipitated overnight with 45% (NH4)2SO4 and centrifuged
(10,000 × g for 30 min at 25°C). The pellet was suspended
in 100 mL of 10 mM Tris–HCl buffer, pH 7.5, containing
5 mM CaCl2, dialyzed four times against 2 L of the same
buffer, and centrifuged (20,000 × g for 30 min at 4°C)
producing extracellular fraction.
The soluble fraction or extracellular fraction were
loaded onto a pre-equilibrated (10 mM Tris–HCl buffer,
pH 7.5, containing 5 mM CaCl2) aprotinin-agarose affin-
ity column (2.5 ml; Sigma-Aldrich). After washing with
20 bed volumes, the material was eluted with 10 mM
Tris–HCl buffer, pH 7.5, containing 1.5 M NaCl. One
mL fractions were collected on ice and the effluents ab-
sorption at 280 nm was monitored to detect protein
peak. Protein fractions were then pooled (LaSP-Sol or
LaSP-Ex), dialyzed against phosphate buffered saline (PBS),
and the protein concentration was quantified by the Lowry
method.
Immunization, infection challenge and evaluation of
disease progression
Animals received 20 μg of LaSP-Sol or LaSP-EX n 20 μL
of PBS by instillation of 10 μL in each nostril using a
micropipette adapted with a polystyrene microtip. A
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PBS alone. Seven days after the vaccine boost, animals
were subcutaneously injected in the hind footpad with
2 × 105 stationary-phase L. amazonensis-GFP promasti-
gotes (7 days of culture). Alternatively, for a lower viru-
lence infection that allowed non-vaccinated controls
not to ulcerate (approximately 3 mm of tickeness) be-
fore 100 days of infection, animals were infected with
2 × 105 promastigotes at the beginning of stationary-
phase of growth (4 days of culture). Lesion sizes were peri-
odically measured with a dial caliper and expressed as the
difference between the thicknesses of infected and contra-
lateral non-infected footpads. For parasite load determin-
ation, the fluorescence intensity of the tissue homogenates
were determined as described previously [11]. Briefly, at
the end of the experiments each infected foot was skinned
and individually homogenized in 1 mL of PBS using a tis-
sue grinder. Tissue debris was removed by gravity sedi-
mentation for 5 min, and then 2-fold serially diluted in
PBS in triplicates for fluorescence intensity measurements
using a plate-reader fluorimeter (FLX 8000, Bio-Tek) at
435 nm excitation and 538 nm emission.
Cytokines
For splenic cells, spleens were isolated at 7 days after
infection, and single-cell suspensions were adjusted
to 4 × 106 per ml in Dulbecco’s minimal essential
medium containing 10% HIFCS, 20 mM HEPES, 50 μM
2-mercaptoethanol, 2 mM L-glutamine, 50 U/ml penicil-
lin, 50 μg/ml streptomycin sulfate (Sigma-Aldrich) and
1 mL samples were plated in 24-well tissue culture. Cells
were cultured for 48 h in the presence of 5 μg/mL of
LaAg, when they were centrifuged and the supernatants
collected. For lymph node cells, at 7 days after infection
the popliteal lymph nodes were isolated and the cells
were cultured as above using 50 ug/mL of LaSP-Sol or
LaSP-Ex. For in situ production, infected footpads were
isolated, skinned, weighed, teased and individually
homogenized in 1 mL of PBS using a glass tissue
homogenizer. The footpad homogenates were centri-
fuged (10 min, 20 000 × g at 4°C) and the supernatants
collected. For cytokine quantification, supernatants pre-
pared as above were assayed for TGF-β, IFN-γ, IL-10,
IL-4, IL-12 and TNF-α by ELISA following the man-
ufacturer’s instructions (R&D Systems, Minneapolis, USA).
For TGF-β, the supernatants were pre-heated to 80°C for
5 min prior to the assay [7].
Statistical analysis
Each experiment was performed three times and similar
patterns of results were achieved. Due to expected varia-
tions among lesion growth rates in PBS controls, the re-
sult is representative of one experiment. The differences
between vaccinated and non-vaccinated groups werestatistically determined by Student t-test or Anova using
the GraphPad InStat software, and were considered signifi-
cant when p ≤ 0.05.
Results
Intranasal vaccination with LaSP-Ex but not LaSP-Sol
protects mice against infection
The efficacy of i.n. vaccination with LaSP-Ex and LaSP-Sol
were evaluated in L. amazonensis-challenged mice seven
days after a booster. Vaccination with LaSP-Sol did not sig-
nificantly alter the course of infection as compared with
controls (Figure 1A). On day 70 of infection, when there
was a slight lesion outgrowth, the parasite loads were
higher than controls (Figure 1B), indicating that i.n. LaSP-
Sol led to increased susceptibility to infection. Opposite to
LaSP-Sol, LaSP-Ex effectively controlled lesion growth
(Figure 1A) and parasite Load (Figure 1B). In the low viru-
lent infection, we followed infections until day 125. We ob-
served a high level of protection by delay of growth curve
and control of the lesion size (Figure 2A). The parasite bur-
den in the footpads was significantly lower than controls
(Figure 2B), confirming the lesion control finding.
Intranasal LaSP-Ex induces Th1 systemic polarization
We evaluated the cytokine production by spleen cells of
LaSP-Ex-vaccinated animals at an early stage of infection
(7 days after challenge). Upon antigen (LaAg)-stimula-
tion, cells form vaccinated mice produced increased
IFN-γ (Figure 3A) and decreased levels of IL-4 and IL-10
(Figure 3B and C), whereas TGF-β was not modulated
(Figure 3D). The cytokine levels from LaSP-Sol-vaccinated
mice were similar to non-vaccinated PBS controls (not
shown), suggesting that the failure of this group may be
related to lack of a proper systemic cytokine modulation.
At the same time, these findings suggest that protective
immunity of LaSP-Ex was associated with a Th1-skewed
cytokine production.
Intranasal LaSP-Ex protection is accompanied by mixed
in situ cytokine responses
To investigate the mechanism of protection of i.n. LaSP-
Ex, the ex vivo production of key pro-inflammatory
(IFN-γ, IL-12 and TNF-α) and anti-inflammatory (IL-4,
IL-10 and TGF-β) cytokines were evaluated in the foot-
pads at the end of the experiments. Figure 4 shows a
higher production of IFN-γ, IL-4 and IL-12 (Figure 4A,
D and E) concomitant with reduced TGF-β and TNF-α
(Figure 4C and F) and unaltered IL-10 (Figure 4B) in re-
lation to non-vaccinated controls, indicating a mixed
pro- and anti-inflammatory local cytokine response.
Discussion
Few vaccines that have been administered by the muco-
sal route are able to stimulate effective cell-mediated
Figure 1 Efficacy of i.n. LaSP-Sol and LaSP-Ex against L. amazonensis infection. BALB/c mice received 20 μg of LaSP-Sol or LaSP-Ex by the i.n. route
on days −14 and −7 of infection. Non-vaccinated controls received PBS alone. On day 0, animals were infected with 2 × 105 stationary-phase
promastigotes of L. amazonensis-GFP (7 days of culture). A) Lesion sizes were measured at the indicated days and are expressed as the difference of
thickness between non-infected and infected footpads. B) The parasite loads were measured on day 70 of infection and are expressed as fluorescence
units (FU). The data displayed are representative of three independent experiments producing the same result profile. Means ± SD (n = 5). *p≤ 0.05
and #p≤ 0.01 in comparison to PBS controls.
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vaccines [17]. Defined leishmanial antigens such as recom-
binant LACK [10,18] and Leish-111f [19] were evaluated
as vaccines by intranasal route against Leishmania infec-
tion. Recombinant LACK [18] and Leish-111f [19] only in-
duced protection by intranasal route when associated with
cholera toxin as adjuvant. However, cholera toxin is not ap-
proved for human use as a mucosal adjuvant [20].
In this work, we evaluated the protectiveness of intra-
nasal vaccination using two new leishmanial serine pro-
tease fractions, LaSP-Sol and LaSP-Ex, without any
adjuvant against L. amazonensis infection. In previous
studies, we showed that those two protease fractions dis-
play different protein contents [12,13]. Subsequently we
showed that intramuscular vaccination with LaSP-Sol
leads to enhanced susceptibility to infection, in a manner
associated with its capacity to stimulate IL-10 and TGF-
beta production by immune cells from 7-day infected
mice [15]. In the present work, using a similar in vitro
model, we observed that contrary to LaSP-Sol, LaSP-Ex
does not stimulate the production of TGF-β, and actuallyFigure 2 Protection duration of i.n. LaSP-Ex upon a less virulent infec
the booster animals were challenged with 2 × 105 at the beginning of stat
described for Figure 1. A) Lesion sizes. B) Parasite loads were measured on d
to PBS controls. The data displayed is representative of two independent exinhibits the spontaneous production of IL-10 (Additional
file 1: Figure S1). The observed differential antigenicity be-
tween these two SP fractions prompted their comparison
as mucosal vaccines. Interestingly, LaSP-Sol is comparable
to LaAg by i.m. immunization [7,15], but not for i.n.
immunization (Figure 1). On the other hand, i.n. LaSP-Ex
vaccination promoted resistance to L. amazonensis chal-
lenge infection (Figures 1 and 2), similar to i.n. LaAg vac-
cination [10]. The ability of adjuvant-free LaSP-Ex to
induce protection is very encouraging, as this is a more de-
fined antigen fraction.
Immunity against Leishmania parasites depends largely
on activation of cell-mediated responses, and gamma
interferon and dendritic cell-derived IL-12 has been
shown to play a crucial role in this process [21]. Whereas
in L. major murine infection, IFN-γ production is more
critical at the beginning of infection [22], in L. ama-
zonensis infection IFN-γ requirement seems particu-
larly important in the later stages [23]. Here, we have
shown the increased production of IFN-γ (Figure 3A) and
decreased production of IL-4 and IL-10 (Figure 3B and C)tion. BALB/c mice were vaccinated with LaSP-Ex and seven days after
ionary-phase L. amazonensis-GFP (4 days of culture) and monitored as
ay 125 of infection. Means ± SD (n = 5). *p≤ 0.05 and #p≤ 0.01 relative
periments.
Figure 3 LaSP-EX induces Th1 systemic polarization. Mice were vaccinated and infected as described for Figure 2. At day 7 of infection, their spleen
cells were re-stimulated in vitro with LaAg (5 μg/mL), and after 48 hours of culture the levels of IFN-γ (A), IL-4 (B), IL-10 (C) and TGF-β (D) were measured
in the supernatants. The data displayed is representative of three independent experiments. Means ± SD (n = 5). *p≤ 0.05 in relation to PBS.
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the systemic Th1 polarization induced by LaSP-Ex intrana-
sal vaccination. LaSP-Ex also led to increased peripheral
IFN-γ (Figure 4A) in the site of infection as compared to
non-vaccinated controls, and this is probably the result ofFigure 4 In situ cytokine profile. Mice were i.n. vaccinated with LaSP-Ex
day 125 of infection, the levels of IFN-γ (A), IL-10 (B), TGF-β (C), IL-4 (D), IL-
expressed as ng per g of footpad. The data displayed is representative of thre
in comparison to PBS controls.increased IL-12 (Figure 4E), which is required not only to
initiate but also to maintain Th1 cell responses and resist-
ance to L. major [24].
Conversely, macrophage deactivating cytokine TGF-β
has been associated with disease [7,25,26]. Also, i.n.and infected with L. amazonensis-GFP as described for Figure 2. On
12 (E) and TNF-α (F) were measured in the lesion homogenates, and
e independent experiments. Means ± SD (n = 5). *p≤ 0.05 and #p≤ 0.01
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tion (Figure 4C) in the infected footpads. This is in line
with our previous studies showing the reversal of TGF-β
production and decreased susceptibility of BALB/c mice
given i.m. LaAg devoid of SP activity [15]. The decrease
of TNF-α (Figure 4F) could be related to the smaller le-
sion observed in the vaccinated group, as it has been
demonstrated in humans that larger lesions are associ-
ated with increase of TNF-α [27]. IL-4 is required for an
optimal Th1 response against L. major, because of the in-
crease in the production of IL-12 by dendritic cells [28].
The increase of IL-4 (Figure 4D) in the footpad of the
vaccinated group suggests the participation of this cyto-
kine in the lesion resolution. Overall, the cytokine balance
indicates that even at this late stage of infection (day 125)
it tends to be a pro-inflammatory local response.
LaSP-Ex is an exogenous purified antigen from L. ama-
zonensis culture. Exogenous antigens from Leishmania
major culture (SEAgs) have been evaluated as vaccine can-
didates against L. major, L. donovani and L. braziliensis in-
fections in BALB/c mice [29,30]. The immunization with
adjuvant-free SEAgs by parenteral route induced protec-
tion against L. major and L. donovani, but not against
L. braziliensis. Two components of SEAgs, GP63 and
nucleoside hydrolase, induced protection against L. major
infection [29-31]. The identity of serine proteases in LASP-
Ex remains unknown. We cloned oligopeptidase B (OPB)
[32] and oligopeptidase B2 (OPB2) [33] from Leishmania
amazonensis and we predicted the molecular weight for
OPB and OPB2 as 83.49 KDa and 103.92 KDa, respect-
ively. We found two protein bands with similar molecu-
lar mass in the extracellular serine proteases fraction of
L. braziliensis [14], suggesting the presence of OPB and
OPB2 in the extracellular serine proteases fraction. Oli-
gopeptidase B is an important virulence factor for try-
panosomatids [34,35]. Studies evaluating the components
of LaSP-Ex and immunogenicity of recombinant OPB
and OPB2 are under way and may help clarify their par-
ticipation in the protective effect of LaSP-Ex. The evalu-
ation of proteases as antigens for immunization is very
important to development of new vaccines against infec-
tious diseases [34,36].
Conclusion
We have previously demonstrated the feasibility of both
oral and intranasal (i.n.) vaccination with particulated
leishmanial antigens (LaAg) in protecting BALB/c mice
against L. amazonensis [10,11] and intranasal DNA en-
coding LACK vaccination protecting BALB/c mice
against L. amazonensis [11]. In this manuscript, we dem-
onstrate that a more defined antigen, extracellular serine
proteases of L. amazonensis, is protective via an intranasal
route encouraging further work on this second-generation
vaccine.Additional file
Additional file 1: Figure S1. In vitro cytokine production by immune
cells stimulated with LaSP-Sol and LaSP-Ex. Lesion-draining lymph node
cells were isolated from 7-day infected mice and re-stimulated in vitro with
50 μg/mL of soluble serine proteases of LaAg (LaSP-Sol) or extracellular
serine proteases fraction (LaSP-Ex). After 48 h, the levels of IL-10 (A), TGF-β
(B) and IFN-γ (C) were measured in the cell supernatants. Means ± SD (n = 5).
*p≤ 0.05 and #p≤ 0.01 in relation to unstimulated controls (medium).
Abbreviations
i.n.: Intransal; i.m: Intramuscular; LaSP-Sol: Soluble Serine proteases from
Leishmania amazonensis promastigotes; LaSP-Ex: Extracellular serine proteases
from Leishmania amazonensis promastigotes supernantant of culture;
SP: Serine proteases.
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